Personalis (NASDAQ:PSNL) SVP Stephen Michael Moore Sells 2,068 Shares of Stock

Personalis, Inc. (NASDAQ:PSNL) SVP Stephen Moore sold 2,068 shares of the business’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.22, for a total value of $33,542.96. Following the completion of the transaction, the senior vice president directly owned 90,257 shares of the company’s stock, valued at approximately $1,463,968.54. This trade represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Personalis Stock Up 0.7%

Personalis stock opened at $16.36 on Wednesday. Personalis, Inc. has a 52 week low of $4.95 and a 52 week high of $18.89. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -15.01 and a beta of 2.31. The business’s 50-day moving average price is $15.09 and its 200 day moving average price is $10.94.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%.The firm had revenue of $22.36 million for the quarter, compared to analyst estimates of $16.69 million. Equities analysts expect that Personalis, Inc. will post -1.07 EPS for the current year.

Wall Street Analyst Weigh In

PSNL has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a report on Friday, July 17th. Craig Hallum lowered Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target on the stock. in a research note on Monday, August 24th. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. TD Cowen restated a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Finally, Needham & Company LLC cut shares of Personalis from a “buy” rating to a “hold” rating in a research report on Monday, July 20th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $14.54.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd lifted its position in shares of Personalis by 76.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after purchasing an additional 1,479 shares during the last quarter. Arizona State Retirement System increased its holdings in Personalis by 28.2% in the second quarter. Arizona State Retirement System now owns 18,766 shares of the company’s stock valued at $251,000 after buying an additional 4,131 shares during the last quarter. Quantbot Technologies LP acquired a new stake in Personalis in the second quarter valued at $69,000. UBS Group AG raised its stake in Personalis by 3.7% in the fourth quarter. UBS Group AG now owns 306,568 shares of the company’s stock valued at $2,440,000 after buying an additional 11,004 shares in the last quarter. Finally, Jasper Ridge Partners L.P. purchased a new stake in Personalis during the 2nd quarter worth about $193,000. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.